These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26681685)

  • 21. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma.
    Martinelli G; Laszlo D; Bertolini F; Pastano R; Mancuso P; Calleri A; Vanazzi A; Santoro P; Cavalli F; Zucca E
    Br J Haematol; 2003 Oct; 123(2):271-7. PubMed ID: 14531908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
    Engelhard M
    Clin Immunol; 2016 Nov; 172():101-104. PubMed ID: 27531574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
    Feugier P
    Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
    Felli V; Di Sibio A; Anselmi M; Gennarelli A; Sucapane P; Splendiani A; Catalucci A; Marini C; Gallucci M
    Neuroradiol J; 2014 Dec; 27(6):657-64. PubMed ID: 25489887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Cvetković RS; Perry CM
    BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ; Heffner LT; Langston AA; Lechowicz MJ; Lonial S; Flowers CR
    Br J Haematol; 2015 Nov; 171(4):539-46. PubMed ID: 26248505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?
    Hegele V; Stoll P; Wüst D; Ehrenbrink G; Grazziotin LR; Caregnato JP; Lindenmeyer LP
    Int J Clin Pharm; 2013 Aug; 35(4):513-9. PubMed ID: 23737385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.
    Lim SH; Linton KM; Collins GP; Dhondt J; Caddy J; Rossiter L; Vadher K; Fines K; Rogers LE; Fernando D; Stanton L; Davies AJ; Johnson PWM; Griffiths G
    Trials; 2018 Nov; 19(1):619. PubMed ID: 30413184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation.
    Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD
    Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
    Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherril B; Ruiz-Soto R; Kaye JA; Hamadani M
    J Oncol Pharm Pract; 2016 Oct; 22(5):666-78. PubMed ID: 26320127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
    Cerchione C; De Renzo A; Di Perna M; Della Pepa R; Pugliese N; Catalano L; Pane F; Picardi M
    Support Care Cancer; 2017 Mar; 25(3):839-845. PubMed ID: 27812763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ten years of rituximab in NHL.
    Winter MC; Hancock BW
    Expert Opin Drug Saf; 2009 Mar; 8(2):223-35. PubMed ID: 19243307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Kruger PC; Cooney JP; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS; Perry CM
    Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.